Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.061 AUD | +1.67% | +1.67% | +38.64% |
Apr. 03 | Acrux, TruPharma Launch Dapsone 5% Gel in US | MT |
Feb. 29 | Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024 |
Sales 2024 * | 6.5M 4.26M | Sales 2025 * | 12.3M 8.06M | Capitalization | 17.73M 11.62M |
---|---|---|---|---|---|
Net income 2024 * | -3M -1.97M | Net income 2025 * | 2M 1.31M | EV / Sales 2024 * | 2.31 x |
Net cash position 2024 * | 2.7M 1.77M | Net cash position 2025 * | 5.2M 3.41M | EV / Sales 2025 * | 1.02 x |
P/E ratio 2024 * |
-4.62
x | P/E ratio 2025 * |
7.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.31% |
Latest transcript on Acrux Limited
1 day | +1.67% | ||
1 week | +1.67% | ||
Current month | +27.08% | ||
1 month | +29.79% | ||
3 months | -10.29% | ||
6 months | +48.78% | ||
Current year | +38.64% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Kotsanis
CEO | Chief Executive Officer | - | 14-11-02 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21-06-20 |
Chief Tech/Sci/R&D Officer | - | 15-02-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Geoff Brooke
BRD | Director/Board Member | 68 | 16-05-31 |
Ross Dobinson
FOU | Founder | 72 | 97-12-31 |
Michael Kotsanis
CEO | Chief Executive Officer | - | 14-11-02 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 0.061 | +1.67% | 151 218 |
24-04-26 | 0.06 | -1.64% | 185,054 |
24-04-24 | 0.061 | -4.69% | 9 |
24-04-23 | 0.064 | +6.67% | 98,691 |
24-04-22 | 0.06 | 0.00% | 135,535 |
Delayed Quote Australian S.E., April 29, 2024 at 02:10 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+38.64% | 11.38M | |
+20.81% | 43.34B | |
+20.44% | 21.96B | |
+12.97% | 14.09B | |
+12.97% | 13.64B | |
+39.74% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- ACR Stock